TRIM24 and cancer: New onset inflammatory myopathy after the age of 40 years, dysphagia, DM, severe skin involvement, persistent disease activity despite immunosuppressive therapy, and anti-TIF1- or anti-NXP2 γ positivity are considered high risk for IIM related to cancer [1].